Group 1: Market Overview - The People's Bank of China conducted a 7-day reverse repo operation of 448 billion yuan at an interest rate of 1.40% on May 27, with 357 billion yuan of reverse repos maturing on the same day [1][5] - A-shares opened slightly lower but showed signs of recovery, with the Shanghai Composite Index fluctuating and turning positive [5][6] - The consumer sector, particularly food and beverage, showed initial strength, while the pharmaceutical sector rebounded [6][12] Group 2: Pharmaceutical Sector - The pharmaceutical and biotechnology sector experienced a partial rebound, with notable stocks such as Longshen Rongfa hitting the daily limit, and Sanofi Guojian rising over 10% [12][13] - Hong Kong pharmaceutical stocks also saw gains, with notable increases in companies like CSPC Pharmaceutical and China Biologic Products [8][14] Group 3: Nuclear Power Sector - The nuclear power sector continued its recent strong performance, with stocks like Shangwei Co. and Rongfa Nuclear Power achieving multiple consecutive gains [9][11] - Recent reports indicate a positive outlook for the controllable nuclear fusion industry, driven by favorable policies and increased financing [11] Group 4: Food and Beverage Sector - The food and beverage sector saw a surge, with stocks like Kuaijishan and Junyao Health achieving significant gains [15][16] - Kuaijishan's market capitalization surpassed that of Guyue Longshan, establishing it as a leading player in the yellow wine industry [15] Group 5: Cultivated Diamond Sector - The cultivated diamond sector experienced a sharp rise, with stocks like Huanghe Xuanfeng and Huifeng Diamond hitting the daily limit [17][18] - Huanghe Xuanfeng announced a partnership to establish a joint venture focused on advanced semiconductor materials, which is expected to enhance the development of high-performance thermal materials [19]

Policy Developments - The National Medical Products Administration (NMPA) has announced the implementation of the "Quality Management Standards for Online Sales of Medical Devices," effective from October 1, 2025. Regulatory authorities are required to guide online sellers and e-commerce platforms in conducting internal training and assessments related to quality management systems, product information display, and risk monitoring [2]. Drug and Device Approvals - BeiGene announced positive results from the Phase 2 clinical trial (DeLLphi-307) of tarlatamab for treating extensive-stage small cell lung cancer (ES-SCLC) patients in China, with detailed data to be presented at an upcoming medical conference [4]. Capital Market Activities - Shanghai BoYin Biotechnology Co., Ltd. has completed a multi-million angel round financing, led by Zhangjiang Life and Health Industry Incubation Angel Fund, with funds aimed at advancing the company's product pipeline and early clinical validation of its first product [7]. Industry Developments - Yuheng Pharmaceutical has signed a co-promotion agreement with Xinghe Pharmaceutical for Pemafibrate, a novel selective PPARα modulator, which will take effect on June 1, 2025. This agreement is expected to enhance Yuheng's product pipeline and potential profit growth, although it will face competition from established products [9]. Shareholder Activities - Chengdu XianDao announced that shareholder Anji Dongfang Jiayu Enterprise Management Partnership reduced its stake by 1 million shares, decreasing its ownership from 6.2% to 5.95% [12]. - BioVeda China RMB Investment Limited plans to reduce its stake in AoJing Medical by up to 135,550 shares, having already reduced its holdings by 34,510 shares, representing 0.25% of the total shares [13].

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-053 哈尔滨誉衡药业股份有限公司 关于与兴和制药（中国）有限公司就佩玛贝特片签订共同推广协议 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、协议签署时间及主要内容 （一）协议签署时间 2025 年 5 月 23 日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）与 兴和制药（中国）有限公司（以下简称"兴和制药"）就"佩玛贝特片"（商品 名：派龙达）签订《共同推广协议》（以下简称"协议"）。 协议将于 2025 年 6 月 1 日生效。 （二）协议主要内容 1、兴和制药授予公司在协议约定区域内推广佩玛贝特片（商品名：派龙达）。 2、公司负责在协议约定区域内推广佩玛贝特片（商品名：派龙达）并履行 协议项下的相关义务。 3、兴和制药将按照协议约定向公司支付服务费及推广支持费。 4、协议初始期限为 2025 年 6 月 1 日至 2027 年 12 月 31 日。如果任何一方 在初始期限结束前六个月未向另一方告知其终止协议的意向，则协议期限将在初 始期限结束后自 ...

Core Viewpoint - The announcement highlights a collaboration between Yuheng Pharmaceutical and Xinghe Pharmaceutical for the promotion of Pemabate Tablets, which is expected to enhance Yuheng's product line and competitiveness in the cardiovascular field [1]. Group 1 - Yuheng Pharmaceutical signed a co-promotion agreement with Xinghe Pharmaceutical on May 23, 2025, for Pemabate Tablets [1]. - The agreement will take effect on June 1, 2025, with an initial term until December 31, 2027, and it can be automatically renewed thereafter [1]. - Xinghe Pharmaceutical authorizes Yuheng Pharmaceutical to promote Pemabate Tablets in designated areas and will pay service and promotional support fees [1]. Group 2 - Pemabate Tablets are the world's first novel high-selectivity PPARα modulator, primarily used to lower triglyceride levels in adult patients with non-familial hypertriglyceridemia [1]. - This collaboration is expected to enrich Yuheng Pharmaceutical's product portfolio and strengthen its competitive position in the cardiovascular sector [1].

Group 1 - The hepatitis concept sector rose by 0.89%, ranking 9th among concept sectors, with 85 stocks increasing in value [1] - Key performers included Haichen Pharmaceutical, which hit a 20% limit up, along with Zhongsheng Pharmaceutical and Haixiang Pharmaceutical also reaching their limit up [1] - Notable gainers included Yangguang Nuohe, Kaipu Biological, and Yuheng Pharmaceutical, with increases of 12.55%, 8.80%, and 5.51% respectively [1] Group 2 - The hepatitis concept sector saw a net inflow of 596 million yuan from main funds, with 57 stocks receiving net inflows [2] - Haichen Pharmaceutical led the net inflow with 179 million yuan, followed closely by Zhongsheng Pharmaceutical and Yuheng Pharmaceutical with 177 million yuan and 155 million yuan respectively [2] - The net inflow ratios for Zhongsheng Pharmaceutical, Haichen Pharmaceutical, and Yuheng Pharmaceutical were 42.93%, 15.92%, and 14.73% respectively [3] Group 3 - The overall market performance showed a mixed trend, with some sectors like controllable nuclear fusion and CRO concepts gaining while military equipment restructuring and other sectors faced declines [2] - The hepatitis concept sector's performance was bolstered by significant capital inflows, indicating strong investor interest [2][3] - The trading volume and turnover rates for leading stocks in the hepatitis sector were notably high, reflecting active trading and investor engagement [3][4]

北京市京轩律师事务所 关于哈尔滨誉衡药业股份有限公司 致哈尔滨誉衡药业股份有限公司： 根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）及中国证券 监督管理委员会《上市公司股东大会规则》（以下简称"《股东大会 规则》"）等法律、法规和规范性文件的规定及《哈尔滨誉衡药业股 份有限公司章程》(以下简称"《公司章程》")的有关规定，北京市 京轩律师事务所（以下简称"本所"）受哈尔滨誉衡药业股份有限公 司（以下简称"公司"）的委托，指派律师参加了公司 2024 年年度 股东大会并就有关事宜出具本法律意见书。 为出具本法律意见书，本所指派律师列席了公司本次股东大会并 审查了公司提供的关于召开本次股东大会的有关文件资料。本所律师 声明如下： 他相关资料（包括但不限于董事会决议、关于召开本次股东大会的公 告、本次股东大会股权登记日的《股东名册》等）的真实性、完整性 和有效性负责。 的召集、召开程序、本次股东大会召集人和出席会议人员的资格、本 次股东大会的表决程序和表决结果发表法律意见，并不对本次股东大 会审议的各项议案内容及其所涉及事实和数据的真实性、合法性发表 意 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-052 哈尔滨誉衡药业股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、现场会议召开时间：2025 年 5 月 16 日 15:00； 2、现场会议召开地点：北京市顺义区空港开发区 B 区裕华路融慧园 28 号 楼一层会议室； 3、会议方式：全体股东采取现场投票、网络投票方式行使表决权； 4、会议召集人：公司董事会； 5、会议主持人：董事长沈臻宇女士； 6、股权登记日：2025 年 5 月 7 日； 7、会议出席情况： | 出席方式 | 股东人数 | 股份总数 | 占有表决权股份总数的比例 | | --- | --- | --- | --- | | 现场参会 | 0 | 0 | 0.0000% | | 网络参会 | 348 | 308,205,072 | 13.7237% | | 合计 | 34 ...

北京市京轩律师事务所 关于哈尔滨誉衡药业股份有限公司 2024 年年度股东大会的法律意见书 致哈尔滨誉衡药业股份有限公司： 根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）及中国证券 监督管理委员会《上市公司股东大会规则》（以下简称"《股东大会 规则》"）等法律、法规和规范性文件的规定及《哈尔滨誉衡药业股 份有限公司章程》(以下简称"《公司章程》")的有关规定，北京市 京轩律师事务所（以下简称"本所"）受哈尔滨誉衡药业股份有限公 司（以下简称"公司"）的委托，指派律师参加了公司 2024 年年度 股东大会并就有关事宜出具本法律意见书。 为出具本法律意见书，本所指派律师列席了公司本次股东大会并 审查了公司提供的关于召开本次股东大会的有关文件资料。本所律师 声明如下： 1、公司应当对向本所律师提供的本次股东大会会议资料以及其 他相关资料（包括但不限于董事会决议、关于召开本次股东大会的公 告、本次股东大会股权登记日的《股东名册》等）的真实性、完整性 和有效性负责。 2、按照《股东大会规则》的要求，本所律师仅对本次股东大会 的召集、召开程序、本次股东大会召集 ...

Group 1: Financial Performance - The company's net profit for 2024 is expected to grow significantly, driven by increased sales of key products, particularly the exclusive traditional Chinese medicine An Nao Wan/Pian, which achieved sales of CNY 182 million, an increase of CNY 81.7 million, representing over 80% year-on-year growth [1] - Sales expenses decreased by 25.82%, management expenses (excluding stock incentive costs) decreased by 18.29%, and financial expenses decreased by 103.41% due to the repayment of all bank loans [2] - The company's operating revenue for 2024 was CNY 2.441 billion, a year-on-year decline of 7.06%, primarily due to the impact of centralized procurement [5] Group 2: Product Growth Expectations - An Nao Wan/Pian is expected to have significant growth potential due to its strong qualifications and untapped market in hospitals, especially tier-three hospitals [3] - The injection of multiple vitamins (12) is anticipated to maintain steady growth, with the company holding over 80% market share [3] - The company expects stable growth for the deer melon peptide injection in 2025 and anticipates significant growth for the new product, Siglitin Metformin Sustained Release Tablets, after its launch in July 2024 [3][4] Group 3: Cost Management and Efficiency - The company aims to continue reducing costs, with sales expenses down 27.63%, financial expenses down 82.43%, and management expenses down 20.97% in Q1 2025 [4] - The company plans to maintain low levels of expenses through improved internal management [4] Group 4: Investment and Shareholder Returns - The company has implemented a share repurchase plan, utilizing approximately CNY 80 million to buy back 32.3 million shares, representing 1.42% of the total share capital prior to the buyback [9] - Future measures to enhance investor returns include focusing on core business, disposing of inefficient assets, and exploring new product opportunities [10] Group 5: Research and Development - The company plans to invest approximately CNY 97 million in R&D for 2024, focusing on generic drugs, with no current investment in innovative drugs [4]

Group 1: Company Performance and Strategy - The company aims to enhance operational efficiency and product sales to improve investor returns, focusing on a "product-first" strategy for sustainable development [2] - The company has over 20 projects under research, with more than 10 applications submitted to CDE for market approval [4][5] - In 2022, the net profit attributable to shareholders was negative due to asset impairment provisions and losses from associated companies [5] Group 2: Stock and Shareholder Information - As of May 9, 2025, the total number of shareholders is approximately 88,000 [5] - 27.9976 million shares of restricted stock were released for trading recently, with compliance to regulatory lock-up and reduction rules for current and former executives [3] - Hu Jin was granted 21.98 million stock options in 2024, with 40% already unlocked, but his shares are currently locked due to his departure from the board [6] Group 3: Future Plans and Market Position - The company will continue to focus on mergers and acquisitions within the pharmaceutical sector, emphasizing innovative and differentiated products [3] - The company does not plan to pursue cross-industry mergers, maintaining a focus on enhancing its product pipeline and leveraging existing capacities [3] - The company has not reported any significant impact on performance from recent supply chain disruptions [5]